Cefuroxime Sodium (sterile) Pharma Grade API is a semi-synthetic second-generation cephalosporin supplied as a white to almost white, hygroscopic crystalline powder. The compendial substance corresponds to CAS 56238-63-2, molecular formula C₁₆H₁₅N₄NaO₈S, and molecular weight 446.37 g/mol. Commercial product models are manufacturer-specific; common descriptors include “Cefuroxime Sodium Sterile EP/USP” and “Cefuroxime Sodium for Injection,” typically packaged in 1 kg, 5 kg, or 10 kg low-density polyethylene double-bag systems within aluminium foil or fibre drums. The sterile grade is intended for aseptic processing into dry-powder injectables, while oral tablet, capsule, and granule formulations ordinarily use the axetil prodrug because cefuroxime sodium exhibits negligible oral bioavailability. The API is controlled under the current USP Cefuroxime Sodium monograph, Ph. Eur. cefuroxime sodium monograph, and JP cefuroxime sodium monograph; injectable grades add sterility and bacterial endotoxin controls aligned with USP <71>, USP <85>, and Ph. Eur. 2.6.1.

How Does the Sterile Sodium Salt Differ from Cefuroxime Axetil in Dosage-Form Selection?

Cefuroxime sodium is freely soluble in water, enabling parenteral reconstitution at clinical concentrations of 100 mg/mL or 200 mg/mL for intramuscular or intravenous administration. Cefuroxime axetil is an acetoxyethyl ester prodrug that is practically insoluble in water and requires dissolution in the gastrointestinal tract before esterase-mediated hydrolysis to cefuroxime. The sodium salt is therefore the only acceptable form for vial-based injection; the axetil form is used for film-coated tablets, capsules, and granules for oral suspension. The oral route is not appropriate for cefuroxime sodium unless a validated permeability-enhancing formulation exists; published data for this specific configuration is limited. A dosage-form decision matrix should include solubility, intestinal permeability, and chemical stability: cefuroxime sodium degrades rapidly in acidic gastric fluid, whereas axetil is formulated with pH-modifying or barrier excipients.

On production-scale fill-finish lines, cefuroxime sodium sterile powder is transferred from double-polyethylene barrier bags into a rotary vial filling machine or an auger-type dosing system within an isolator or restricted access barrier system. The powder’s hygroscopicity requires room air conditions not exceeding 30% RH and 20–25°C; excursions above 40% RH are associated with agglomeration, erratic auger discharge, and vial mass variability. Type I borosilicate glass vials with bromobutyl rubber stoppers and flip-off aluminium seals are standard. Dry powder filling is preferred because cefuroxime sodium in aqueous solution degrades by β-lactam ring hydrolysis; reconstituted solutions may be stored for 24 h at 2–8°C in a clinical setting. Unlike lyophilized cephalosporin presentations, cefuroxime sodium vials are often filled as dry sterile powder and reconstituted immediately before administration; this avoids lyophilization cycle losses but places greater burden on API particle-size control and humidity management. Sterility assurance depends on pre-filtration of the bulk drug solution through 0.22 µm sterilizing-grade filters followed by aseptic crystallization, drying, and filling; no terminal sterilization step exists. Admixture with aminoglycoside antibiotics in a single intravenous container is avoided because cephalosporins can inactivate gentamicin or amikacin through ring-opening interactions; separate infusion lines are used.

Quality Attributes Governed by USP <71>, USP <85>, and Ph. Eur. 2.6.1

The sterile injectable grade is not defined solely by assay; it adds particulate, endotoxin, and sterility controls that oral cefuroxime axetil monographs do not require at the same level. The following test matrix is usually documented in the certificate of analysis for a sterile cefuroxime sodium API lot.

Despite the product name listing tablet, capsule, and granule presentations, the direct use of cefuroxime sodium in oral solid dosage forms is not regarded as a standard pharmaceutical development approach. Cefuroxime axetil, not the sodium salt, is the oral precursor in compendial tablet and suspension monographs. Oral granules for suspension typically employ coated cefuroxime axetil particles embedded in sucrose or sorbitol-based vehicles with xanthan gum or hydroxypropylcellulose as suspending agents; the ester is protected from acid-catalyzed hydrolysis by the film coat. If a tablet or capsule product requires cefuroxime sodium, preformulation data should include pH-solubility profile in simulated gastric fluid at pH 1.2 and fasted-state simulated intestinal fluid at pH 6.8, but published data for this specific configuration is limited. Capsule formulations with cefuroxime axetil often require dry blending or roller compaction because wet granulation with water hydrolyzes the ester and produces bitter-tasting cefuroxime.

When High-Shear Granulation or Roller Compaction Is Applied to Cefuroxime-Containing Formulations

For oral axetil formulations, high-shear granulation with aqueous binder is generally avoided; roller compaction or slugging is used to densify the API-excipient blend without exposing the ester to water. Cefuroxime axetil exhibits low flowability and sticking; blending with microcrystalline cellulose, crospovidone, magnesium stearate, and colloidal silicon dioxide is common. If cefuroxime sodium is used in a non-sterile granule, the process must be non-aqueous or dry granulation, because the sodium salt is hygroscopic and wets quickly above 40% RH. For tablet cores, compression force is adjusted to target hardness of 60–120 N and friability below 1.0% per USP <1216>; disintegration time for immediate-release tablets is typically not more than 15 min in water at 37°C per compendial test. These parameters are product-specific and must be validated against dissolution acceptance criteria.

Cefuroxime sodium’s pharmacological position is second-generation cephalosporin. Compared with cefazolin sodium, a first-generation cephalosporin, cefuroxime sodium has an α-methoxyimino substituent that stabilizes the β-lactam ring against many TEM-1 penicillinases and extends activity against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae. Compared with ceftriaxone sodium or cefotaxime sodium, third-generation agents, cefuroxime sodium has less activity against Enterobacterales and lacks clinically relevant activity against Pseudomonas aeruginosa, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus. It also does not penetrate the blood-brain barrier sufficiently for meningitis monotherapy, whereas cefotaxime and ceftriaxone are used in central nervous system infections. Cefuroxime sodium is eliminated primarily by renal excretion of unchanged drug; dose adjustment is required when creatinine clearance falls below 20–30 mL/min, whereas ceftriaxone has significant biliary elimination and requires less renal dose adjustment. Protein binding of cefuroxime sodium is approximately 33–50%, compared with 85–95% for ceftriaxone. Enterococcus spp. and Bacteroides fragilis are intrinsically resistant.

Residual Solvent and Elemental Impurity Control Strategies

Residual solvent profiling for cefuroxime sodium is batch-dependent because different synthetic routes use acetone, methanol, ethyl acetate, or dichloromethane. The API manufacturer must demonstrate compliance with ICH Q3C, with Class 1 solvents absent and Class 2 solvents below 5000 ppm, 3000 ppm, and 600 ppm for acetone, methanol, and dichloromethane respectively. Elemental impurity control follows ICH Q3D; for a parenteral route, the permitted daily exposure for elemental impurities is derived from the maximum daily dose of 1.5 g cefuroxime sodium. Palladium and platinum catalysts are common; their levels are typically controlled to less than 10 µg/g or tighter if process validation supports it. Any specification exception must be justified in the pharmaceutical quality system under change control.

Current drug master files for cefuroxime sodium sterile grade should include stability data generated per ICH Q1A(R2) at 25°C/60% RH long-term and 40°C/75% RH accelerated, container closure integrity testing per USP <1207>, and bacterial endotoxin trending per USP <85>. The retest period is assigned from long-term data; because cefuroxime sodium is hygroscopic, open-container hold time studies usually restrict repeated opening of the sterile barrier to maintain water content below 3.5%. Dry powder vials should be stored protected from light at 15–25°C; freezing and refrigeration are not required.